Geron Reiterates 2026 RYTELO Net Product Revenue Guidance of $220 Million-$240 Million
Bitget2026/10/29 11:59- Geron discontinued its IMpactMF trial of imetelstat in relapsed or refractory myelofibrosis in October 2026.
- Expected 2026 RYTELO net product revenue remains $220 million-$240 million, with total operating expenses projected at $230 million-$240 million.
- RYTELO net product revenue rose 17% year over year in the second quarter; demand volume increased 5% sequentially.
- Plans call for communicating RYTELO's European commercial strategy for lower-risk myelodysplastic syndromes by the end of 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Arbitrum will welcome a new propAMM
Crypto prices
More
